Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early versus late risankizumab treatment and tissue-resident memory T cells in moderate-to-severe psoriasis
2025-521424-30-00Phase 3Authorised
- Sponsor
- ICR Medical
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of risankizumab in plaque psoriasis and psoriasis (2 arms), sponsored by ICR Medical. Primary endpoint: Change in epidermal and dermal CD8+CD103+ TRM cells at week 16 from baseline lesional levels. Planned start Sep 2026; status: authorised.
02
Drugs
risankizumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2025-521424-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521424-30-00.